$10.33
+0.01
(+0.1%)▲
0.0%
Downside
Day's Volatility :0.72%
Upside
0.72%
25.51%
Downside
52 Weeks Volatility :26.05%
Upside
0.72%
Period | Haleon Plc Spon Ads | Index (Russel 2000) |
---|---|---|
3 Months | 21.24% | 0.0% |
6 Months | 20.82% | 0.0% |
1 Year | 28.48% | 0.0% |
3 Years | 39.41% | -22.3% |
Market Capitalization | 47.1B |
Book Value | $1.82 |
Dividend Share | 0.062 |
Dividend Yield | 1.53% |
Earnings Per Share (EPS) | 0.31 |
PE Ratio | 33.32 |
PEG Ratio | 1.47 |
Wall Street Target Price | 10.57 |
Profit Margin | 9.66% |
Operating Margin TTM | 23.14% |
Return On Assets TTM | 4.45% |
Return On Equity TTM | 6.82% |
Revenue TTM | 11.3B |
Revenue Per Share TTM | 2.45 |
Quarterly Revenue Growth YOY | 0.8% |
Gross Profit TTM | 6.7B |
EBITDA | 2.6B |
Diluted Eps TTM | 0.31 |
Quarterly Earnings Growth YOY | 0.03 |
EPS Estimate Current Year | 0.39 |
EPS Estimate Next Year | 0.43 |
EPS Estimate Current Quarter | 0.09 |
EPS Estimate Next Quarter | 0.11 |
What analysts predicted
Upside of 2.32%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.1B | - |
Net Income | 857.6M | - |
Net Profit Margin | 7.72% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 13.3B | ↑ 16.65% |
Net Income | 1.5B | ↑ 74.81% |
Net Profit Margin | 11.58% | ↑ 3.86% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 12.7B | ↓ 3.51% |
Net Income | 1.8B | ↑ 21.4% |
Net Profit Margin | 14.56% | ↑ 2.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 13.2B | ↑ 13.76% |
Net Income | 1.3B | ↓ 23.74% |
Net Profit Margin | 9.76% | ↓ 4.8% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 14.3B | ↑ 4.09% |
Net Income | 1.3B | ↓ 1.04% |
Net Profit Margin | 9.28% | ↓ 0.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.6B | ↓ 21.28% |
Net Income | 471.9M | ↑ 96.46% |
Net Profit Margin | 13.03% | ↑ 7.81% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5B | ↓ 6.3% |
Net Income | 460.9M | ↓ 6.17% |
Net Profit Margin | 13.05% | ↑ 0.02% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5B | ↑ 0.0% |
Net Income | 453.0M | ↑ 0.0% |
Net Profit Margin | 13.05% | ↑ 0.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↑ 4.32% |
Net Income | 535.5M | ↑ 15.89% |
Net Profit Margin | 14.49% | ↑ 1.44% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.7B | ↑ 0.0% |
Net Income | 537.6M | ↑ 0.0% |
Net Profit Margin | 14.49% | ↑ 0.0% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.5B | ↓ 4.93% |
Net Income | 385.1M | ↓ 28.37% |
Net Profit Margin | 10.92% | ↓ 3.57% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 46.8B | - |
Total Liabilities | 10.9B | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 45.8B | ↓ 4.43% |
Total Liabilities | 10.6B | ↓ 4.72% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 45.8B | ↑ 0.94% |
Total Liabilities | 10.6B | ↑ 0.81% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 42.4B | ↑ 1.06% |
Total Liabilities | 22.3B | ↑ 130.31% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 43.1B | ↓ 2.18% |
Total Liabilities | 21.9B | ↓ 5.62% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.1B | - |
Total Liabilities | 22.2B | - |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.1B | - |
Total Liabilities | 21.9B | - |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 42.4B | - |
Total Liabilities | 21.2B | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.0B | - |
Investing Cash Flow | 381.0M | - |
Financing Cash Flow | -1.2B | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↑ 79.01% |
Investing Cash Flow | 1.4B | ↑ 253.95% |
Financing Cash Flow | -3.3B | ↑ 163.46% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↓ 3.62% |
Investing Cash Flow | -43.9M | ↓ 103.2% |
Financing Cash Flow | -1.6B | ↓ 49.28% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.5B | ↑ 52.14% |
Investing Cash Flow | -10.7B | ↑ 26518.18% |
Financing Cash Flow | 8.4B | ↓ 659.14% |
Q1 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 162.2M | - |
Investing Cash Flow | 321.0M | - |
Financing Cash Flow | -496.3M | - |
Q2 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 476.5M | ↑ 190.6% |
Investing Cash Flow | -6.0B | ↓ 1954.64% |
Financing Cash Flow | 6.0B | ↓ 1293.58% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 448.0M | ↑ 0.0% |
Investing Cash Flow | -5.7B | ↑ 0.0% |
Financing Cash Flow | 5.6B | ↑ 0.0% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 838.7M | ↑ 100.0% |
Investing Cash Flow | -10.6B | ↑ 100.0% |
Financing Cash Flow | 10.5B | ↑ 100.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 74.3M | ↓ 91.03% |
Investing Cash Flow | -10.7B | ↑ 2.29% |
Financing Cash Flow | 8.4B | ↓ 19.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 945.8M | ↑ 1127.87% |
Investing Cash Flow | -237.4M | ↓ 97.86% |
Financing Cash Flow | -856.1M | ↓ 109.81% |
Sell
Neutral
Buy
Haleon Plc Spon Ads is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Haleon Plc Spon Ads | 7.49% | 20.82% | 28.48% | 39.41% | 39.41% |
![]() Neurocrine Biosciences Inc. | -16.62% | -11.2% | 10.78% | 28.21% | 20.17% |
![]() Zoetis Inc. | 2.41% | 4.25% | 0.77% | -8.94% | 49.4% |
![]() Viatris Inc. | -0.79% | -8.6% | 12.7% | -23.12% | -31.03% |
![]() Catalent, Inc. | 0.82% | 6.48% | 22.57% | -57.47% | 16.16% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Haleon Plc Spon Ads | 33.32 | 33.32 | 1.47 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
![]() Neurocrine Biosciences Inc. | 36.53 | 36.53 | 0.27 | 4.57 | 0.16 | 0.12 | NA | 24.87 |
![]() Zoetis Inc. | 36.6 | 36.6 | 2.61 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
![]() Viatris Inc. | 224.4 | NA | 0.07 | 2.68 | -0.03 | 0.03 | 0.04 | 16.36 |
![]() Catalent, Inc. | 211.02 | NA | 2.87 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Haleon Plc Spon Ads | Buy | $47.1B | 39.41% | 33.32 | 9.66% |
![]() Neurocrine Biosciences Inc. | Buy | $12.2B | 20.17% | 36.53 | 16.0% |
![]() Zoetis Inc. | Buy | $85.7B | 49.4% | 36.6 | 26.29% |
![]() Viatris Inc. | Hold | $13.5B | -31.03% | 224.4 | -4.24% |
![]() Catalent, Inc. | Hold | $10.9B | 16.16% | 211.02 | -23.81% |
Insights on Haleon Plc Spon Ads
Revenue is down for the last 2 quarters, 2.91B → 2.77B (in $), with an average decrease of 4.9% per quarter
Netprofit is down for the last 2 quarters, 423.0M → 303.0M (in $), with an average decrease of 28.4% per quarter
Dodge & Cox
FMR Inc
ClearBridge Advisors, LLC
Fisher Asset Management, LLC
Wellington Management Company LLP
AllianceBernstein L.P.
In the quarter ending March,2024. Haleon Plc Spon Ads has declared dividend of $0.11
Read MoreOrganization | Haleon Plc Spon Ads |
Employees | 25408 |
CEO | Mr. Brian James McNamara |
Industry | Healthcare |